Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
JTECTSE:3446 -0.21%56 Return-on-Tangible-Equity is -6.41% as of Mar. 2026. GuruFocus rates TSE:3446 with a GF Score™ of 56/100 and a GF Value™ of 円2,140.06 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 758 Medical Devices & Instruments companies, JTEC ranks worse than 52.24% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. JTEC's annualized net income for the quarter that ended in Mar. 2026 was 円-154 Mil. JTEC's average shareholder tangible equity for the quarter that ended in Mar. 2026 was 円2,395 Mil. Therefore, JTEC's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was -6.41%.
The historical rank and industry rank for JTEC's Return-on-Tangible-Equity or its related term are showing as below:
TSE:3446'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -1.76 Med: 10.47 Max: 22.32
Current: 3.26
During the past 9 years, JTEC's highest Return-on-Tangible-Equity was 22.32%. The lowest was -1.76%. And the median was 10.47%.
TSE:3446's Return-on-Tangible-Equity is ranked worse than 52.24% of 758
companies
in the Medical Devices & Instruments industry
Industry Median: 4.055
vs TSE:3446: 3.26
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
JTEC Return-on-Tangible-Equity Related Terms
JTEC Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for JTEC's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:3446 vs ISRG, BDX, MDLN: Return-on-Tangible-Equity Comparison
For the Medical Instruments & Supplies subindustry, JTEC's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
JTEC Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, JTEC's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where JTEC's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of -6.41% mean?
JTEC (TSE:3446) has a Return-on-Tangible-Equity of -6.41% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JTEC and its competitors. According to the industry distribution chart, JTEC ranks #396 out of 758 companies in the Medical Devices & Instruments industry, placing it in the top 52.2%.
Is JTEC's Return-on-Tangible-Equity too high?
JTEC's current Return-on-Tangible-Equity is -6.41%. Based on the distribution chart, JTEC ranks #396 out of 758 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, JTEC has a GF Score™ of 56/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does JTEC's Return-on-Tangible-Equity compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, JTEC ranks #396 out of 758 companies for Return-on-Tangible-Equity. This places JTEC in the lower half of its industry. The industry median Return-on-Tangible-Equity is 4.06. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.06, based on 758 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on JTEC and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. JTEC's current Return-on-Tangible-Equity is -6.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is JTEC stock overvalued right now?
Based on GuruFocus' analysis, JTEC (TSE:3446) is currently considered Significantly Undervalued. The stock's GF Value™ is 円2,140.06, compared to a current price of 円1,440.00 — trading 32.7% below its estimated fair value. The current Return-on-Tangible-Equity is -6.41%. JTEC's overall GF Score™ is 56/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For JTEC (TSE:3446), the current Return-on-Tangible-Equity is -6.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is JTEC (TSE:3446) Overvalued in 2026?
Based on GuruFocus' analysis, JTEC stock appears to be undervalued.
The current stock price of 円1,440.00 is trading 32.7% below its estimated GF Value™ of 円2,140.06.
GuruFocus considers JTEC to be Significantly Undervalued.
Key valuation signals for TSE:3446:
Return-on-Tangible-Equity: -6.41%
GF Value™: 円2,140.06 vs. price of 円1,440.00 (32.7% below fair value)
No single metric tells the full story. See the TSE:3446 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
JTEC Corp is engaged in developing, designing, manufacturing and sales of Automated Cell Culture System; X-ray Mirrors for Synchrotron Facilities; and Automated System in various fields. Its products in optical business include Kirkpatrick-Baez (KB) mirror, Advanced KB mirror (1D Wolter mirror), Montel mirror, Ellipsoidal mirror, 2D Walter mirror, Deformable mirror, Multi-channel mirror, X-ray focusing alignment system (JM1000 / 2000 series), Additional mirror shaping improvement, and Mirror coating. Its products in life science include CELLFLOAT products and Automated Cell Culture Systems.
56GF Score
Get the complete analysis for TSE:3446
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:3446 has been successfully added to your 
